High prices for drugs for rare diseases have introduced uncertainties from payers around whether a medication’s value justifies its price.Read More
Author: Isha Bangia
Dr. Isha Bangia brings a combination of clinical and strategic experience to Certara. She holds a PharmD from Rutgers University and an MBA from Johns Hopkins. Her background as a pharmacist provides clinical perspective into retail and hospital settings where she has been involved in market access and clinical care at the provider level. Isha has also participated in P&T committee meetings for formulary decisions. Prior to joining Certara, Isha was a consultant at Prescient Healthcare Group, focused on competitive landscaping and go-to-market strategies. She has past experience from Zitter Health Insights focused on payer primary and secondary market research to better understand market access barriers (e.g. step therapies and prior authorizations) for manufacturers. She has worked across multiple therapeutic areas including oncology, biosimilars, diabetes, vaccines, and rare diseases.